Andere talen CRISPR Therapeutics AG

Aandelen

CRSP

CH0334081137

Geschatte realtime Cboe BZX Andere beurzen 18:58:55 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
53,37 ^USD	-4,10%		-5,16%	-14,92%

18/04	CRISPR THERAPEUTICS AG : Citigroup ontvangt een koopadvies	ZM
17/04	Insider bij Crispr Therapeutics verkocht aandelen ter waarde van $1.173.232, volgens een recent SEC-document	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene and Cell Therapy 2024 Annual Meeting	23/04
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	22/04
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	17/04
Harvard University: How to realize immense promise of gene editing	17/04
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference	03/04
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	01/04
Recent Appellate Decision Overturns Revocations Of Broad Institute CRISPR-Cas9 Patents	26/03
CRISPR Therapeutics Proposes New Appointment to the Board of Directors	13/03
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	21/02
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M	21/02
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10	21/02
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21/02
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing	16/02
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit	15/02
CRISPR Therapeutics - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	14/02
CRISPR Therapeutics to Sell About $280 Million of Common Shares	13/02
CRISPR Therapeutics Announces $280 Million Registered Direct Offering	13/02
Vertex secures European approval for CRISPR cell therapy	13/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CRISPR Therapeutics AG

Aandelen

CRSP

CH0334081137

Andere talen

Filters